Loading...
•
Jun 30, 2025
STERIS Q1 2026 Earnings Report
STERIS delivered solid Q1 2026 results, achieving strong revenue and earnings growth across all major segments.
Key Takeaways
STERIS reported $1.39 billion in revenue and $177.4 million in net income for Q1 2026. EPS was $1.79 and adjusted EPS reached $2.34. All three core segments contributed to top-line growth, led by strong performance in Healthcare and Applied Sterilization Technologies (AST).
Revenue rose to $1.39 billion, an 8.7% increase year-over-year.
Net income attributable to shareholders was $177.4 million.
Free cash flow increased to $326.5 million, supporting continued investment and shareholder returns.
Healthcare and AST segments saw double-digit revenue and operating income growth.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
STERIS reaffirmed its full-year FY2026 outlook with adjusted EPS projected between $9.90 and $10.15, supported by strong organic growth and operating leverage.
Positive Outlook
- Raised dividend and delivered strong free cash flow of $326.5 million
- Healthcare segment maintained double-digit service growth
- Continued backlog growth in Healthcare and Life Sciences
- Strong earnings leverage with 8.7% top-line growth translating to 25.5% net income growth
- Reaffirmed FY26 adjusted EPS guidance of $9.90–$10.15
Challenges Ahead
- Life Sciences service growth was modest at 3.4%
- Currency exchange movements slightly dampened revenue growth
- Capital expenditures remained high at $93.6 million
- Healthcare backlog growth may indicate longer fulfillment cycles
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...